Antibiotics Market Demand, Size, Share & Forecast 2032

Antibiotics Market: Industry Perspective

The global antibiotics market size was worth around USD 39.44 billion in 2023 and is predicted to grow to around USD 54.87 billion by 2032 with a compound annual growth rate (CAGR) of roughly 3.86% between 2024 and 2032. The report offers an assessment and analysis of the Antibiotics market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, sales estimates, opportunities, evolving trends, and industry-validated data.

Request Free Sample

In the first half of the twentieth century, illness due to contagious agents caused most of the deaths in North America as well as across the globe. However, with the discovery of penicillin in 1928 and the medical utilization of sulphonamides in 1930, antibiotic treatment gained prominence. With extensive usage of penicillin in the 1940s and the introduction of new kinds of antibiotics within the next two decades, the market begins to gain traction. From 1935 till 2003 many new types of antibiotics were introduced and including sulphonamides, penicillin, aminoglycosides, cephalosporin, chloramphenicol, tetracycline, macrolides, glycopeptides, rapamycin, nitroimidazoles, quinolones, oxazolidinones, and lipopeptides.

Request Free Sample

Moreover, the launching of new antibiotics was considered to eradicate contagious diseases. However, with resurgence of new diseases and the threat of bioterrorism & genetically engineered pathogens like Bacillus anthracis has compelled the researchers to develop new antibiotics. Hence, with the occurrence of new types of antimicrobial-resistant microbes, it has become necessary to create new antibiotics to combat these microbes. This has also resulted in the growing significance of antibiotic drug treatment in the current years. With the spread of COVID-19 across the globe, the antibiotics industry is likely to flourish over the coming decades.

According to the Lancet, WHO classified antibiotic intake into three categories namely, Watch, Reserve, and Access for seventy-six nations from 2000 to 2015.

Antibiotics Market: Growth Dynamics

The surge in the incidences of chronic disorders has resulted in the demand for the development of new medicines and this is likely to translate into market expansion over the estimated timespan. Growing efforts as well as investments made by the key firms in research & development for producing new drugs will prompt the expansion of the antibiotics industry over the forecast timespan.

Furthermore, favorable government laws like generating antibiotic incentives now are projected to expedite the development of antibiotic treatments against pathogens and this will steer the market growth. The need for curbing chronic ailments including Zika virus, pneumonia, COVID-19, cancer, tuberculosis, Ebola virus, and malaria will provide impetus to the growth of the industry over the estimated timespan. Product innovation as well as addition of new products to existing product lines as well as private-public strategic alliances & joint ventures will prop up the market size in the foreseeable future.

Antibiotics Market: Report Scope

Antibiotics Market: Regional Analysis

• Asia Pacific market to record tremendous growth over the forecast period

The growth of the market in the Asia Pacific zone over 2024-2032 is owing to high incidences of contagious ailments, regulations promoting the use of generic medicines, and favorable government laws. Additionally, inflating population and unhygienic conditions will further contribute towards the regional industry growth.

Antibiotics Market: Competitive Analysis

The global antibiotics market is dominated by players like:

• Novartis AG
• Bayer AG
• Janssen Pharmaceuticals
• Astellas Pharma, Inc.
• Pfizer, Inc.
• GlaxoSmithKline plc
• Bristol Myers Squibb Company
• Abbott Laboratories
• Sanofi S.A.
• Eli Lilly and Company

The global antibiotics market is segmented as follows:

By Action Mechanism Segment Analysis

• Cell Wall Synthesis Inhibitors
• Protein Synthesis Inhibitors
• DNA Synthesis Inhibitors
• RNA Synthesis Inhibitors
• Mycolic Acid Inhibitors

By Drug Class Segment Analysis

• Cephalosporin
• Penicillin
• Fluoroquinolone
• Macrolides
• Carbapenem
• Aminoglycosides
• Sulfonamides
• Other

By Regional Segment Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa